Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Italy Fines Apple €98.6 Million Over App Store Dominance 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
SAN DIEGO, Oct. 24, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycan’s, today announced the appointment of Philippe Schaison to its Board of Directors effective immediately.
"We are thrilled to have Philippe join the SENTÉ team,” said Faheem Hasnain, Chairman of the Board of Directors of SENTÉ. “He brings a tremendous set of expertise and validation to our company during this exciting next phase of growth. Philippe is a high ranking industry veteran and will be a valuable asset in helping the company evolve into a major aesthetics contender.”
Mr. Schaison brings to SENTÉ over 20 years of experience in the skin care industry. Currently, he is Chief Executive Officer of Syneron Candela North America and Global Executive Vice President Strategy and Business Development. Most recently he served as President of Allergan US Aesthetic and Dermatology, where he led a $2 billion U.S. Aesthetic and Dermatology business since 2013, with responsibility for Allergan's top aesthetic brands, including Botox, Juvederm, Kybella and SkinMedica, and other leading brands. Prior to Allergan, Mr. Schaison served in leadership roles at several aesthetic businesses, including Clarins, Johnson & Johnson where he served as VP of Global Skin Care, and L’Oréal. Mr. Schaison received a Master of Business Administration in Marketing from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy from the University of Paris V.
"I am excited and honored to have the opportunity to play a key role in SENTÉ’s already robust and experienced Board of Directors,” said Philippe Schaison. “SENTÉ has assembled a world class team and a market disrupting technology that the aesthetics industry has been waiting for. I am looking forward to being a part of this compelling growth story and helping SENTÉ become a leading brand in the space.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycan’s. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through its exclusive network of physicians and medically supervised spas.
Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
